Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

XENE stock hub

Xenon Pharmaceuticals Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

XENEis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

5.5B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

XENE

In the news

Latest news · XENE

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-37.5

P25 -105.6P50 -46.5P75 -3.1

ROIC-25.1

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All XENE market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

185

Groups with data

Currency

USD

Showing 185 of 185 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001582313
Company name	Xenon Pharmaceuticals Inc.
Country	Canada
Country code	US
Cusip	98420N105
Employees	370
Employees Change	43%
Employees Change Percent	13.15
Enterprise value	$4.1B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2014-11-05
Isin	CA98420N1050
Last refreshed	2026-05-10
Market cap	$5.5B
Market cap category	Mid-Cap
Price	$56.44
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	XENE
Website	https://www.xenon-pharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-7.02%
FCF yield	-5.63%
P/B ratio	4.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-328.2M
Net Income	$-383.2M
Net Income Growth Years	0%
Profit Per Employee	$-1M
ROA	-24.22
Roa5y	-18.62
ROCE	-30.64
ROE	-37.53
Roe5y	-28.66
ROIC	-25.07

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	23.77%
Cagr1y	59.8%
Cagr3y	9.98%
Cagr5y	24.98%
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$1.4B
Cash	$1.1B
Current Assets	$1.1B
Current Liabilities	$39.8M
Debt	$7.5M
Debt Equity	$0.01
Equity	$1.3B
Liabilities	$49M
Long Term Assets	$280.2M
Long Term Liabilities	$9.2M
Net Cash	$1.3B
Net Cash By Market Cap	$24.42
Net Cash Growth	95.2%
Net Debt Equity	$-1
Tangible Book Value	$1.3B
Tangible Book Value Per Share	$13.85
WACC	7.83

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	27.79
Net Working Capital	$-26.4M
Quick ratio	27.53
Working Capital	$1.1B

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-4.16%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	743.65%
1Y total return	59.75%
200-day SMA	43.9
3Y total return	33.05%
50-day SMA	55.11
50-day SMA vs 200-day SMA	50over200
5Y total return	204.92%
All Time High	63.95
All Time High Change	-11.74%
All Time High Date	2026-03-10
All Time Low	2.1
All Time Low Change	2,587.62%
All Time Low Date	2017-11-16
ATR	2.04
Beta	0.65
Beta1y	-0.11
Beta2y	0.75
Ch YTD	25.93
High	57.47
High52	63.95
High52 Date	2026-03-10
High52ch	-11.74%
Low	55.73
Low52	28.19
Low52 Date	2025-05-30
Low52ch	100.21%
Ma50ch	2.42%
Premarket Change Percent	1.27
Premarket Price	$56.71
Premarket Volume	1,189
Price vs 200-day SMA	28.56%
RSI	51.07
RSI Monthly	65.89
RSI Weekly	67.32
Sharpe ratio	0.96x
Sortino ratio	2.29
Total Return	-4.16%
Tr YTD	25.93
Tr1m	-2.1%
Tr1w	0.55%
Tr3m	36.39%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	11
Analyst Count Top	7
Analyst Price Target Top	$62.71
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-1.19
Earnings Revenue Estimate	3,800,000x
Earnings Revenue Estimate Growth	-49.33x
Operating Income	$-412.7M
Price target	$70.55
Price Target Change	$25
Price Target Change Top	$11.11

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	91,105,169%
Float Percent	94.25%
Shares Insiders	0.12%
Shares Institutions	83.02%
Shares Out	96,665,550
Shares Qo Q	9.01%
Shares Yo Y	4.16%
Short Float	5.33%
Short Ratio	4.13
Short Shares	5.02

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-365.7M
Average Volume	919,414.2x
Bv Per Share	13.85
CAPEX	$-889,000
Ch10y	743.6
Ch1m	-2.1
Ch1w	0.55
Ch1y	59.75
Ch3m	36.39
Ch3y	33.05
Ch5y	204.9
Ch6m	47.56
Change	0.79%
Change From Open	0.55
Close	56
Days Gap	0.23
Depreciation Amortization	2,471,000
Dollar Volume	51,955,672.7
Earnings Date	2026-05-07
Earnings Time	amc
EBIT	$-412.7M
EBITDA	$-410.2M
EPS	$-4.71
F Score	2
FCF	$-307.3M
FCF EV Yield	-7.45x
FCF Per Share	$-3.18
Financing CF	958,975,000
Fiscal Year End	December
Founded	1,996
Income Tax	$-2M
Investing CF	-223,794,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-26
Ma150	46.41
Ma150ch	21.61%
Ma20	56.93
Ma20ch	-0.86%
Net CF	429,210,000
Next Earnings Date	2026-08-10
Open	56.13
Optionable	Yes
Position In Range	40.8
Ppne	14,582,000
Pre Close	56
Price Date	2026-05-08
Ptbv Ratio	4.08
Relative Volume	1x
Share Based Comp	58,427,000
Tr6m	47.56%
Volume	920,547
Z Score	36.19

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does XENE pay a dividend?

Capital-return profile for this ticker.

Performance

XENE stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns XENE?

Insider, institutional, and short-interest positioning.

Institutional ownership

+83.0%

Float: +94.2% of shares outstanding

Insider ownership

+0.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

XENE momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

51.1

Neutral momentum band

Price vs 200-day MA

+28.6%

50/200-day relationship not available

Beta (5Y)

0.65

Less volatile than the market

Sharpe ratio

0.96

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About XENE

Hub-level FAQ points readers to the deeper analysis pages.

What is the current XENE stock rating?

Xenon Pharmaceuticals Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full XENE analysis?

The full report lives at /stocks/XENE/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for XENE?

The latest report frames XENE around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the XENE page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.